A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Meanwhile, Lilly gets in on the next-gen KRAS action.
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
But will the FDA accept the surrogate endpoint used in ASC4First?
This weekend’s oncology conference will feature at least 30 different ADC projects.